BIOGEN INC. - COMMON STOCK

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

28 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

26 Oct 2024 20:15:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

25 Oct 2024 16:10:18 By NetDania Notify

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

24 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

22 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

09 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

08 Oct 2024 10:05:33 By NetDania Notify

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

08 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

07 Oct 2024 12:25:18 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

03 Oct 2024 09:45:05 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

02 Oct 2024 15:08:16 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

25 Sep 2024 16:06:38 By NetDania Notify

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

24 Sep 2024 01:00:00 By Nasdaq GlobeNewswire

Biogen Board Appoints Two New Independent Directors

12 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

04 Sep 2024 07:30:34 By Nasdaq GlobeNewswire

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024

30 Jul 2024 17:15:17 By Nasdaq GlobeNewswire

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

30 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

26 Jul 2024 07:20:38 By Nasdaq GlobeNewswire

Biogen Completes Acquisition of Human Immunology Biosciences

02 Jul 2024 09:16:51 By Nasdaq GlobeNewswire

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

27 Jun 2024 19:39:36 By Nasdaq GlobeNewswire